P15 (MTS2) gene is a candidate tumor suppressor gene localized adjacent to the p16 gene at 9p21. Deletions at the 9p21 region frequently affect both p16 and p15 genes, however, mutations in the coding sequence of the p15 gene have not been found in the majority of tumors analyzed, including nonHodgkin's lymphomas. Abnormal methylation of the promoter region of p15 has been recently described as an alternative mechanism of inactivation of this gene. We analyzed 72 nonHodgkin's lymphomas (NHL) for methylation at p15 exon 1 by PCR and Southern blot techniques using methylation-sensitive restriction enzymes. Abnormal methylation was found in eight cases (11%), most of them (three MALT, one anaplastic T cell lymphoma, one Burkitt and one follicular lymphoma) showing hypermethylation in the p16 gene also. In contrast, two pleomorphic T cell NHL showed a selective methylation at p15 gene, while the p16 gene remained unmethylated. The results show that methylation at the p15 gene is frequently associated with p16 methylation in NHL, and suggest that selective methylation of p15, although uncommon, could be a specific alteration implicated in T cell NHL.
Introduction
The p15 gene (also called MTS2/CDKN2B/ink4b) is located close to the p16 gene, at chromosome 9p21, a region frequently deleted in many tumor cell lines. 1, 2 It encodes a cyclin-dependent kinase 4 and 6 inhibitor, with a sequence and structure similar to the p16 gene 1, 3 which is a suppressor gene implicated in a wide variety of tumors. This suggests that the p15 gene may also be an important tumor suppressor gene. In addition, the p15 gene, but not p16, is transcriptionally induced by transforming growth factor ␤ (TGF-␤), which is a potent inhibitor of cell growth 4 indicating a possible role for p15 in G1 arrest of cells.
Strong evidence of inactivation of the p16 gene through homozygous and hemizygous deletions, 1,2,5-8 germinal and somatic mutations, [9] [10] [11] [12] and methylation of its 5Ј CpG island [13] [14] [15] [16] [17] have been reported. The p15 gene is frequently codeleted with the p16 gene in deletions affecting the 9p21 region, although mutations in the coding region of p15 have not been found in most tumor types, including hematological malignancies. 3, [18] [19] [20] [21] This fact indicates that p16, and not p15, might be the principal target of these deletions. 22, 23 Recently, aberrant methylation of p15 5Ј CpG island has been found to occur selectively at the p15 gene in a high proportion of gliomas and leukemias. 24 Also, p15 hypermethylation has been implicated in transformation from myelodysplasic syndromes to overt leukemia. 25 This methylation was related to loss of transcription of the gene, since treatment with demethylating agents, such as 5-aza-2Ј deoxycytidine, leads to re-expression of p15 mRNA, suggesting that it would be an alternative mechanism of inactivation of p15 gene. 26 The methylation status of p15 gene in non-Hodgkin's lymphoma (NHL) has not been analyzed in detail. In the present study, we analyzed the methylation status of the p15 exon 1 which lies on the 5Ј CpG island of the gene. In a group of 72 NHL previously studied for methylation and mutations at the p16 gene, 17 we investigated if aberrant methylation selectively affects p15 and if this alteration is more frequent in certain types of lymphoma.
Material and methods
Tumor samples DNA were extracted from tumor samples of 72 lymphomas of different subtypes diagnosed according to Kiel and Issacson's classifications at the Pathology Department of the Fundacion Jimenez Diaz. This group of lymphomas included 56 B cell NHL (38 nodal lymphomas and 18 extranodal lymphomas) and 16 T cell NHL (Table 1) . We also obtained DNA from five reactive tonsils as lymphoid tissue controls.
All samples had been previously studied for the p16 gene to know their methylation status of exon 1. 
PCR methylation analysis
The pattern of methylation at exon 1 of the p15 gene was analyzed by PCR ( Figure 1 ). Two micrograms of genomic DNA were firstly digested with 20 units of three different methylation-sensitive restriction enzymes: SacII, HpaII and Hhal, and then p15 exon 1 was amplified in a multiplex PCR together with exon 11 of the p53 gene, which has been used as an internal control of the PCR. Primers for p15 exon 1 and p53 exon 11 have been previously described. 3, 27 In the p15 exon 1 fragment there is one restriction site for Sacll enzyme, two Hpall sites and seven Hhal sites (Figure 1) . PCR was performed as follows: 200 ng of digested DNA were mixed with a PCR reaction in 50 l of final volume, containing 1 × PCR reaction buffer, 200 M of dNTP, 50 pmol each of p15 exon 1 primers and 30 pmol of p53 exon 11 primers and 1 unit of Taq polymerase. PCR conditions were 94°C for 5 min, 30 cycles of 94°C for 1 min, 56°C for 1 min and 72°C for 1 min. PCR products were resolved on a 3% agarose gel. After digestion with these enzymes, exon 1 of the p15 gene was amplified only in lymphomas in which restriction sites of the enzymes were protected by abnormal methylation, and digestion was not possible. In the case of digestion with HpaII and HhaI enzymes, which present more than one restriction site in the amplified fragment, methylated exon 1 can be detected only when all restriction sites of these enzymes are methylated. All samples showed exon 11 of p53, which does not present restriction sites for the enzymes used.
Southern blot methylation analysis
Methylated cases at SacII site were confirmed by Southern analysis. Five micrograms of DNA were digested with HindIII and SacII enzymes overnight. HindIII fragment contains the 5Ј CpG island where exon 1 of p15 is located, similar to that in the p16 gene. In this HindIII fragment there is one restriction site for SacII. Digestion with only HindIII enzyme generates a fragment of 2.8 kb, and when SacII site is not protected by methylation, a shorter fragment of 2.6 kb is obtained after double digestion (Figure 2 ).
The digested DNA was run on 0.8% agarose gels, and then transferred to a nylon membrane. Filters were hybridized with a PCR generated probe of exon 1, using the same primers as described for the PCR methylation analysis. Hybridization was performed at 65°C overnight, followed by stringent washes.
In methylated cases, the SacII enzyme cannot digest the HindIII fragment, and it is possible to obtain the 2.8 kb band,
Figure 1
Restriction map of the methylation-sensitive enzymes used in this study. Arrows indicate the primers used to amplify p15 exon 1 in the PCR methylation assay.
Figure 2
Schematic representation of methylation analysis by Southern blot of the p15 gene. The restriction sites for HindIII and SacII, and the expected fragments generated by digestion with HindIII alone or the double digestion with HindIII and SacII are represented.
while only the 2.6 kb band is detected in unmethylated lymphomas.
Results
PCR and Southern blot analysis were performed to detect p15 methylation. All samples included in this work were previously studied for p16 methylation 17 using a similar method. The methylation status of exon 1 of the p15 gene was investigated by PCR at the restriction sites of three different enzymes: SacII, HpaII and HhaI. Methylation at SacII site was also studied by Southern blot technique.
We have found an abnormal methylation pattern, at least for one of the restriction sites studied, in 8/72 (11%) NHL (Table 1) . These eight lymphomas included 3/18 (17%) MALT lymphomas (two high-grade and one low-grade), 3/16 (19%) T cell lymphomas and 2/38 (5%) nodal B cell NHL that correspond to one follicular and one Burkitt lymphoma. However, none of the reactive tonsils analyzed appeared to be methylated at the p15 exon 1. In methylated cases, variation in the distribution of the methylation at the restriction sites of the enzymes was found. In the three MALT lymphomas methylation affected the HpaII restriction sites (Table 2 ). Both methylated B cells NHLs and one of the T cell lymphomas showed abnormal methylation only at the SacII site, while the other two methylated T lymphomas showed methylation at the restriction sites of more than one of the enzymes analyzed. In an anaplastic T cell lymphoma (ALCL-T) all restriction sites included in this study were methylated (Table 2) .
By PCR technique we can only detect methylation at HpaII, 
MET, methylated sites; −, non-methylated sites; ?, in these cases we only confirm methylation when all restriction sites for these enzymes are methylated. It is possible, however, that some of the restriction sites are methylated.
Figure 3
Methylation status of the p15 exon 1 analyzed by PCR. Exon 11 of the p53 gene was used as an internal control, and amplified in all cases. The presence of an amplified exon 1, indicated that the site was methylated. In this example PCR were performed after the digestion with HpaII. Lanes 1, 7: undigested controls; lanes 2, 3: non-methylated cases; lanes 4-6: methylated lymphomas; lane 8: marker 1 kb DNA ladder (Gibco BRL, European Division).
which has two different restriction sites in p15 exon 1, when both sites are methylated. The same occurs for HhaI, which has eight restriction sites in exon 1, and amplification of p15 exon 1 after digestion with HhaI is only possible when the eight HhaI restriction sites are protected by methylation (Figure 1) . Thus, it is not possible to evaluate whether in some apparently unmethylated cases, methylation really affected some, but not all, the restriction sites of HpaII or HhaI.
As shown in Figure 3 , it is possible to amplify exon 1 after digestion with SacII, HpaII or HhaI only in methylated cases, while exon 11 of p53, used as an internal control of the PCR, can be amplified in all cases. The SacII site was also analyzed by Southern blot (Figure 4 ). All cases showing methylation at the SacII site by PCR technique, were confirmed by Southern
Figure 4
Methylation analysis at the 5Ј CpG island of the p15 gene by Southern blot. Cases were digested using HindIII and SacII enzymes and hybridized with an exon 1 probe. Size of the fragments in kb are specified on the left. Lanes 1 and 2 correspond to methylated cases showing a 2.8 kb band. Also shown is a 2.6 kb fragment, indicating that they are not completely methylated. Lane 3: unmethylated lymphoma; lane 4: DNA sample digested only with HindIII, that originated a fragment of 2.8 kb.
blot analysis. All these cases showed the 2.8 kb band, corresponding to methylated DNA, and a nonmethylated 2.6 kb band, probably as a result of partial methylation in tumor cells or perhaps due to the contaminating normal cells localized around the tumor cells. However, unmethylated lymphomas and the reactive tonsils only displayed the unmethylated band (Figure 4) .
Comparison of results between the methylation study of p15 gene and the methylation status of p16 gene in the same tumors, revealed that in most of these lymphomas p15 gene methylation occurred in association with methylation of the p16 gene. In all B cell NHL, nodal and MALT, and in the ALCL-T, aberrant methylation involves both p16 and p15 genes. However, the two other T cell lymphomas showed that methylation affected only the p15 gene ( Table 2) .
Discussion
Many recent studies have attempted to prove the tumor suppressor role of the p15 gene in different types of cancer. The p15 gene seems to be a good candidate for a tumor suppressor gene because of its similarity to the p16 gene. 4 The p16 suppressor gene has been found to be inactivated mainly through homozygous deletions in some primary tumors, 5, 7 but mutations in the p16 gene are infrequent in many primary tumor types. 28, 29 An alternative mechanism of inactivation of the p16 gene is through abnormal methylation of its 5Ј CpG island. [13] [14] [15] [16] Both p16 and p15 genes are located on chromosome 9p21, a region frequently deleted in tumors. These deletions usually involve both genes, and selective deletions of p15, while maintaining intact the p16 gene, are very rare and have only been found in some gliomas. 3 In most of the tumors analyzed no mutations in the coding sequence of p15 have been found. However, aberrant methylation of the 5Ј CpG island of the p15 gene could be an alternative mechanism of inactivation of this gene, as occurs for p16 gene. In some hematologic malignancies, inactivation of p15 gene through abnormal methylation has been described. This alteration has been found mainly in acute myeloid and lymphoid leukemias (AML and ALL), and less frequently in NHLs. 26, [30] [31] [32] Because homozygous deletions at 9p21, affecting p16 and p15 genes, generally occur with low frequency in NHLs, and point mutations are rare in the p16 gene and are not found in the p15 gene, [33] [34] [35] [36] [37] we examined the methylation status of the p15 gene in 72 NHL of different subtypes, previously studied for the p16 gene, to investigate the implication of this alteration in the development of lymphomas.
Our results reveal that methylation is present at p15 exon 1 in about 11% of NHL, generally in association with p16 methylation. The percentage of abnormal p15 methylation is probably underestimated, because it is possible that we have not detected cases in which other restriction sites, not analyzed in this study, were methylated. Also, in the PCR methylation analysis using HpaII and HhaI enzymes, it is possible that some cases presented methylation only at some, but not all, restriction sites of these enzymes.
Selective methylation of p15, without p16 methylation, occurred in two T cell NHL. However, RNA from these two T cell lymphomas were not available to assess whether p15 is expressed in these tumors. These lymphomas were found to belong to the same histopathologic subgroup both being T cell lymphomas with pleomorphic morphology. This fact suggests that methylation at the p15 gene may be a specific alteration in this group of lymphomas, although the number of cases is small.
Among the group of MALT lymphomas analyzed in this study, 3/18 cases (17%) showed methylation at p15 exon 1. However, it cannot be considered a selective methylation of the p15 gene because all these cases also displayed methylation at the p16 gene. As we have previously described, 17 MALT lymphomas showed a high incidence (67%) of p16 methylation. Thus, methylation at the p15 gene seems to be less frequent than p16 methylation in MALT lymphomas. It is possible that in these cases methylation affects the p15 gene only as a result of its proximity to the p16 gene, and the relevance of inactivation by methylation of both p16 and p15 remains to be analyzed. It is also possible that cooperation between the p16 and p15 genes exists, and that the inactivation by methylation of these genes could be involved in the development of lymphomas.
Among the nodal B cell NHL analyzed, we have found abnormal methylation of the p15 gene in only two out of 38 lymphomas. In these cases, as also occurred in the three methylated MALT lymphomas, methylation affected both the p16 and p15 genes. In our previous study, we described that p16 methylation occurs in B cell NHL in a higher proportion than p15 methylation, indicating a major implication of the p16 gene in these tumors. However, the finding that two T cell NHLs selectively methylate the p15 gene suggests a role for this gene, at least in some types of lymphomas.
Some works have described that methylation of the p16 CpG island is associated with loss of transcription of the gene and the treatment with demethylating agents leads to reexpression of p16 mRNA. 15, 16 This suggests that aberrant methylation of the p15 gene could be an alternative mechanism of inactivation of this gene also in NHL, and that it mainly affects MALT and T cell lymphomas. The methylation analysis through methylation-sensitive restriction enzymes provides information about punctual methylation in the 5Ј CpG island. In our study, the methylated cases analyzed present aberrant methylation at one or some restriction sites. This increment of methyl groups in the promoter region is likely to have an effect on gene expression. 38 However, it remains to be proven that methylation at p15 exon 1 correlates with transcriptional silencing of the gene in these tumors. In addition, some leukemia cell lines have described the inactivation of the p15 gene through methylation and these were resistant to activation by TGF-␤, a potent growth inhibitor of hematopoietic cells, 20 and this fact provided additional evidence of a tumor suppressor role for p15 gene.
In summary, methylation at the p15 gene could be an alteration that affects nearly 11% of NHL. We have described that aberrant methylation at the p15 gene occurs together with methylation at the p16 gene in most of the lymphomas analyzed. The exceptions were two T cell lymphomas in which p15 methylation occurred while maintaining the p16 gene unmethylated, suggesting that p15 methylation could be a selective alteration at least for some groups of lymphomas.
